Insulin types, onset, peak and timing for the NCLEX
Insulin questions connect the ordered product and route with meal timing, glucose monitoring and hypoglycemia prevention. Onset, peak and duration are useful estimates, but they do not replace the medication label, current order, patient response or facility protocol.
Safety boundary
Do not use a study-guide timing table to calculate a dose, change an insulin regimen or assume that two products share the same route or mixing instructions. Verify the exact generic and brand name, concentration, device, route, order, glucose result and relationship to food before administration.
Category estimates, not universal clocks
| Category | Representative example | Onset | Peak | Duration |
|---|---|---|---|---|
| Rapid-acting | Insulin lispro | About 15 min | About 1 h | 2–4 h |
| Regular/short-acting | Regular human insulin | About 30 min | 2–3 h | 3–6 h |
| Intermediate-acting | NPH insulin | 2–4 h | 4–12 h | 12–18 h |
| Long-acting | Insulin glargine | About 2 h | No pronounced peak | Up to 24 h |
| Ultra-long-acting | Product-specific | About 6 h | No pronounced peak | 36 h or longer |
These are category-level teaching estimates. CDC notes that brands within the same category can differ and that absorption and action vary among people. Use the exact product information for clinical decisions.
Evidence for this section: CDC insulin types and the Lantus label.
Maximum glucose-lowering effect increases hypoglycemia risk, but it is not a universal clock. Risk also changes with the product, dose, meal timing, activity, injection site, kidney or liver function, concurrent medications and the patient's prior response. Long- and ultra-long-acting products may not have a pronounced peak.
Route, meal timing and preparation are product-specific
- Meal timing: the insulin lispro label permits subcutaneous administration within 15 minutes before a meal or immediately afterward. Other rapid-acting products can have different instructions, so verify the exact label and order.
- Intravenous use: regular human insulin is not the only insulin that can ever be given IV. Some insulin lispro and insulin aspart products permit supervised IV infusion with close glucose and potassium monitoring. Never infer an IV route from the category alone.
- Mixing: insulin glargine must not be diluted or mixed with another insulin or solution. Compatibility is product-specific rather than a blanket rule for every long-acting insulin.
- Resuspension: follow the device instructions for cloudy suspensions. Humulin N instructions specify gentle rolling and inversion with an appearance check; vigorous shaking is not the instruction.
Evidence for this section: the insulin lispro, Humulin N and Lantus labels.
Mix only when the exact products are compatible
The Humulin N label permits mixing with Humulin R or Humalog when indicated. Draw the clear Humulin R or Humalog into the syringe first, then the cloudy Humulin N, and inject immediately after mixing. This product-specific instruction supports the “clear before cloudy” memory aid; it does not authorize mixing arbitrary insulins. Do not mix insulin glargine.
Recognizing and responding to hypoglycemia
Symptoms can begin quickly and vary by person. Shaking, sweating, hunger, anxiety, dizziness, tachycardia, irritability or confusion can occur; severe hypoglycemia can cause inability to self-treat, seizure or loss of consciousness.
For a conscious person who can swallow and whose glucose is below the individualized target, follow the applicable protocol. A common approach is 15 grams of fast-acting carbohydrate, recheck in about 15 minutes, and repeat if the glucose remains low. Once the glucose is in a safer range, add a carbohydrate-and-protein snack only when the next meal is more than an hour away or the care plan directs it.
If swallowing is unsafe or the person cannot self-treat, do not give oral carbohydrate. Activate the emergency protocol and use the ordered non-oral treatment, such as glucagon or IV dextrose, with continued monitoring.
Evidence for this section: MedlinePlus low-blood-sugar self-care and the insulin lispro label.
The beta-blocker interaction
Beta-blockers and other drugs that block sympathetic activity can blunt or eliminate some warning signs of hypoglycemia, and beta-blockers may increase or decrease insulin's glucose-lowering effect. Do not assume that sweating will persist or that confusion will be the first sign. The insulin lispro and insulin glargine labels call for closer glucose monitoring when medications can reduce symptom awareness.
Common questions
When is hypoglycemia risk highest after insulin?
Risk often rises near the product's maximum glucose-lowering effect, but generic peak tables are only estimates. The exact insulin, dose, meal timing, activity, organ function, concurrent medicines and patient response all matter; some basal insulins have no pronounced peak.
Is regular insulin the only insulin that can be given intravenously?
No. Regular human insulin and some rapid-acting products, including certain insulin lispro and insulin aspart formulations, may be administered IV under medical supervision with product-specific preparation and close glucose and potassium monitoring. Verify the exact label, route and order.
What order is used when compatible clear and cloudy insulins are mixed?
For the products specifically permitted by the Humulin N label, draw clear Humulin R or Humalog first, then cloudy Humulin N, and inject immediately. Do not generalize this instruction to incompatible products; insulin glargine must not be mixed.
How is mild hypoglycemia treated when the client can swallow?
Follow the clinical protocol. A common approach is 15 grams of fast-acting carbohydrate, recheck in about 15 minutes, and repeat if glucose remains low. If the client cannot swallow or self-treat, do not give oral carbohydrate; activate the emergency protocol for ordered non-oral treatment.
Sources and further reading
- CDC — Types of Insulin — Centers for Disease Control and Prevention; evidence locator: Terms to know; insulin types table; brand and patient variability qualification; source updated ; accessed
- Insulin Lispro Injection Prescribing Information — DailyMed, U.S. National Library of Medicine; evidence locator: Dosage and Administration — subcutaneous meal timing and supervised intravenous infusion; Warnings and Precautions — hypoglycemia; Drug Interactions — beta-blockers and other agents that blunt symptoms; source updated ; accessed
- Insulin Aspart Injection Prescribing Information — DailyMed, U.S. National Library of Medicine; evidence locator: Dosage and Administration — supervised intravenous administration, dilution, and close glucose and potassium monitoring; Clinical Pharmacology — variability of onset, peak, and duration; source updated ; accessed
- Humulin N Prescribing Information and Instructions for Use — DailyMed, U.S. National Library of Medicine; evidence locator: Dosage and Administration — mixing with Humulin R or Humalog; Instructions for Use — rolling, inverting, and appearance checks; source updated ; accessed
- Lantus Insulin Glargine Prescribing Information — DailyMed, U.S. National Library of Medicine; evidence locator: Dosage and Administration — do not mix or administer intravenously; Pharmacokinetics — 24-hour profile without a pronounced peak; Drug Interactions — blunted hypoglycemia symptoms; source updated ; accessed
- MedlinePlus — Low blood sugar: self-care — U.S. National Library of Medicine; evidence locator: When Your Blood Sugar Gets Low — 15 grams, 15-minute recheck, repeat treatment, and conditional follow-up snack; source updated ; accessed
- NCSBN — 2026 RN Test Plan — National Council of State Boards of Nursing; evidence locator: 2026 RN Test Plan; effective April 1, 2026–March 31, 2029; source updated ; accessed
Practice this for real. PulseRN includes insulin timing in both flashcards and full clinical scenarios.